Research Project

xr:d:DAFPkcp-DjU:115,j:3594696590,t:23042806
Antimalarial drug development from several Indonesian endemic plants
2024

The currently available malaria prophylactic drugs remain limited, and the issue of parasite resistance to antimalarial agents has necessitated this study\'s long-term goal of identifying and producing alternative malaria prophylactic drugs for individuals traveling to malaria-endemic regions. In Indonesia, Papua remains an endemic area where parasite resistance to artemisinin, the first-line antimalarial drug, has been reported. This study specifically aims to develop a formulation that consistently produces a product with nanoparticle characteristics that meet the required criteria and to determine the optimal dosage for malaria prevention in experimental animals or in vitro parasite inhibition. Additionally, toxicity tests will be conducted to assess the safety of the developed nanoparticles.

The methodology includes extracting Carica papaya L. (papaya) or Moringa oleifera (moringa) leaves, followed by nanoparticle formulation using chitosan. The formulated nanoparticles will be characterized and subsequently tested for malaria prophylactic efficacy in experimental animals. The test subjects will receive the drug before being injected with Plasmodium berghei malaria parasites to evaluate the inhibitory effect on parasite growth. Furthermore, an in vitro assay will be performed on Plasmodium falciparum cultures to assess the inhibition of parasite growth, as this species is the primary cause of malaria in humans. To ensure the formulation’s safety, toxicity tests will also be conducted on experimental animals.

Vaccine
An Immune system against Covid-19 Infection
2023

To fight the COVID-19 pandemic, immunity against SARS-CoV-2 should be achieved not only through natural infection but also by vaccination. The effect of COVID-19 vaccination on previously infected persons is debatable. Methods: A prospective cohort was undergone to collect sera from unvaccinated survivors and vaccinated persons—with and without COVID-19 pre-infection. The sera were analyzed for the anti-receptor binding domain (RBD) titers by ELISA and for the capacity to neutralize the pseudovirus of the Wuhan-Hu-1 strain by luciferase assays. Vaccination with whole-inactivated vaccines does not increase the antibody titer against RBD in individuals with pre-existing immunity. Moreover, the viral neutralization capacity of vaccine serum is relatively low compared with that of the convalescent serum. However, the vaccine may be crucial in preventing the disease among people without an infection history.